Trial Profile
An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of Avalglucosidase Alfa (NeoGAA, GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Avalglucosidase alfa (Primary) ; Alglucosidase alfa
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Acronyms Mini-COMET
- Sponsors Sanofi Genzyme
- 06 Feb 2024 Results published in the Sanofi Media Release.
- 05 Feb 2024 Results presented in a Sanofi Media Release.
- 05 Feb 2024 According to a Sanofi media release, findings from this study will be featured at the 20th annual WORLDSymposiumTM.